Thiohydroxamates as inhibitors of histone deacetylase
AssigneePharmacyclics, Inc.
InventorsDarren Magda, Zhong Wang
Life of this patent
Estimating the term…
Abstract
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase. Also described herein are methods of using such HDAC inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC activity.
Claims17
A compound of Formula (IIa):
- wherein:
- Y is alkylene optionally substituted with cycloalkyl, optionally substituted phenyl, alkylthio, alkylsulfinyl, alkysulfonyl, optionally substituted phenylalkylthio, optionally substituted phenylalkylsulfonyl, hydroxy, or optionally substituted phenoxy;
- R3 is hydrogen, alkyl, hydroxyalkyl, or optionally substituted phenyl;
- and
- Ar2 is aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where Ar2 is substituted or unsubstituted;
- or
- a pharmaceutically acceptable salt thereof.
A 1,3-disubstituted-1H-indole-6-thiohydroxamic acid compound, wherein the substituent at the 1-position is —X2—R2 and the substituent at the 3-position is R3, wherein:
- X2 is a bond, or a substituted or unsubstituted group selected from among C1-C6alkylene, C2-C6alkenylene, C2-C6 alkynylene, C1-C6-fluoroalkylene, C2-C6-fluoroalkenylene, C1-C6haloalkylene, C2-C6haloalkenylene, C1-C6heteroalkylene;
- C(═O)—, and C(═O)—C1-C6alkylene;
- R2 is a substituted or unsubstituted group selected from among aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
- where if R2 is substituted, then each substituent on R2 is selected from among hydrogen, halogen, —CN, —NO2, —S(═O)2NH2, —CO2H, —CO2R10, —C(═O)R11, —S—R11, —S(═O)—R11, —S(═O)2—R11, —NR10C(═O)—R11, —C(═O)N(R10)2, —S(═O)2N(R10)2, —NR10S(═O)2—R11, —OC(═O)N(R10)2, —NR10C(═O)O—R11, —OC(═O)O—R11, —NHC(═O)NH—R11, —OC(═O)—R11;
- —N(R10)2, substituted or unsubstituted C1-C6alkyl, C1-C6-fluoroalkyl, substituted or unsubstituted C2-C6alkenyl, substituted or unsubstituted C2-C6alkynyl, substituted or unsubstituted C1-C6alkoxy, C1-C6 fluoroalkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- R10 is hydrogen, or a substituted or unsubstituted group selected from among C1-C6alkyl, C1-C6fluoroalkyl, C1-C6heteroalkyl, C3-C8cycloalkyl, C2-C8heterocycloalkyl, aryl, and heteroaryl;
- R11 is a substituted or unsubstituted group selected from among C1-C6alkyl, C1-C6fluoroalkyl, C3-C8cycloalkyl, C2-C8heterocycloalkyl, aryl, and heteroaryl;
- R3 is hydrogen, halogen, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C2-C6alkenyl, substituted or unsubstituted C2-C6alkynyl, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6fluoroalkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted phenyl, or —X6—R6;
- X6 is a C1-C6alkylene, C1-C6fluoroalkylene, C2-C6alkenylene, C2-C6heteroalkylene;
- R6 is hydrogen, halogen, —CN, hydroxy, amino, C1-C6alkylamino, di(C1-C6alkyl)amino, C1-C6alkoxy, C3-C8cycloalkyl, C2-C8heterocycloalkyl, phenyl, heteroaryl, or X7—R7
- X7 is a bond, —O—, —S—, —S(═O)—, —S(═O)2—, —NRa—, —C(═O)—, —C(═O)O—, —OC(═O)—, —NHC(═O)—, —C(═O)NRa—, —S(═O)2NRa—, —NHS(═O)2—, —OC(═O)NRa—, —NHC(═O)O—, —OC(═O)O—, —NHC(═O)NRa—;
- R7 is hydrogen, C1-C6alkyl, C2-C6alkenyl, C1-C6heteroalkyl, C1-C6haloalkyl, C3-C8cycloalkyl, cycloalkylalkyl, C2-C8heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
- Ra is selected from among hydrogen, C1-C6alkyl, C2-C6alkenyl, hydroxy, C1-C6alkoxy, C1-C6fluoroalkoxy, C1-C6heteroalkyl;
- or
- Ra and R7 together with the N atom to which they are attached form a 5-, 6-, or 7-membered heterocycloalkyl;
- or an active metabolite, pharmaceutically acceptable solvate, pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, or pharmaceutically acceptable prodrug thereof.
A method of improving the pharmacokinetic properties of a hydroxamic acid HDAC inhibitor compound, wherein said method comprises replacing the hydroxamic acid functional group of the hydroxamic acid HDAC inhibitor compound with a thiohydroxamic functional group to provide a thiohydroxamic acid HDAC inhibitor compound.
Dependencies are inferred from the claim text.